Quarterly results round-up: Bard and Zimmer in line, while Grifols stays strong
This article was originally published in Clinica
Executive Summary
CR Bard posted 4% year-on-year growth for its first fiscal quarter, with revenue reaching $730m, while net profit rose 5% to $138.7m. This performance, described as "unremarkable but stable" by Morgan Stanley analyst David Lewis, was "mostly inline" with analysts' expectations.